Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.7.49 (
reverse transcriptase
)
31,746
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
ADAM metallopeptidase domain 29
(
ADAM29
) belongs to the ADAM family, is a type I integral membrane protein and secrets a glycoprotein that mediates cell-cell and cell-matrix interaction. Aberrant expression of
ADAM29
is involved in a number of physiological processes diversification. The purpose of the present study was to investigate the expression and biological effect of
ADAM29
in human gastric cancer (GC) specimens and cell lines
in vitro
. The expression of
ADAM29
was examined in 83 GC samples and 25 adjacent normal gastric tissues using quantitative
reverse transcriptase
-quantitative polymerase chain reaction and immunohistochemistry. The association between
ADAM29
expression and cellular function of GC cells was assessed
in vitro
. The
ADAM29
mRNA levels were significantly elevated in GC tissues compared with paracancerous tissues. Increased levels of
ADAM29
were associated with high-grade staging and high Tumor-Node-Metastasis stages. Kaplan-Meier survival curves demonstrated that patients with GC and low
ADAM29
transcript levels exhibited longer overall survival (OS) (P<0.01) and progression-free survival (PFS) time (P<0.01) compared with patients with high
ADAM29
expression levels.
ADAM29
significantly promoted the proliferation, migration and invasion of GC cells
in vitro
when overexpressed in MGC803 cells and knocked down in AGS cells.
ADAM29
was increased in GC and the elevated expression of
ADAM29
was associated with a poor survival rate of patients.
ADAM29
may become a prognostic factor and therapeutic candidate for human GC.
...
PMID:Clinical significance of ADAM29 promoting the invasion and growth of gastric cancer cells
in vitro
. 3000 27
